<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20231006" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2023-10-06_to_2023-10-06" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-06_to_2023-10-06">0000318154</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2023-10-06_to_2023-10-06" name="dei:AmendmentFlag" contextRef="duration_2023-10-06_to_2023-10-06">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20231006.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-06_to_2023-10-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-06</xbrli:startDate> <xbrli:endDate>2023-10-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-06</xbrli:startDate> <xbrli:endDate>2023-10-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-06</xbrli:startDate> <xbrli:endDate>2023-10-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-06_to_2023-10-06">8-K</ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p><p style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-06_to_2023-10-06" format="ixt:date-monthname-day-year-en">October&#160;6, 2023</ix:nonNumeric></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityRegistrantName">Amgen Inc.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityFileNumber">001-37702</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityTaxIdentificationNumber">95-3540776</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-06_to_2023-10-06">One Amgen Center Drive</ix:nonNumeric><br /><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-06_to_2023-10-06">Thousand Oaks</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-06_to_2023-10-06" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-06_to_2023-10-06">91320-1799</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table><p style="margin-top:10pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code:</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:CityAreaCode">805</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:LocalPhoneNumber">447-1000</ix:nonNumeric></span></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed since Last Report)</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities Registered under Section 12(b) of the Act:</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-06_to_2023-10-06_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter). Emerging growth company <ix:nonNumeric contextRef="duration_2023-10-06_to_2023-10-06" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&#160;</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Introductory Note</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;6, 2023, Amgen Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Amgen</span>&#8221;), Horizon Therapeutics plc, a public limited company incorporated under the laws of Ireland (&#8220;<span style="text-decoration:underline">Horizon</span>&#8221;), and Pillartree Limited, a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of Amgen (&#8220;<span style="text-decoration:underline">Acquirer Sub</span>&#8221;), completed the transactions contemplated by that certain Transaction Agreement (the &#8220;<span style="text-decoration:underline">Transaction Agreement</span>&#8221;), dated as of December&#160;11, 2022, by and among Amgen, Horizon and Acquirer Sub. Pursuant to a court-sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the &#8220;<span style="text-decoration:underline">Scheme</span>&#8221;), Acquirer Sub acquired the entire issued ordinary share capital of Horizon (the &#8220;<span style="text-decoration:underline">Acquisition</span>&#8221;) and Horizon became a wholly-owned subsidiary of Amgen.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;2.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Completion of Acquisition or Disposition of Assets.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Acquisition was conditioned on, among other things, the sanction of the Scheme by the Irish High Court (the &#8220;<span style="text-decoration:underline">Court</span>&#8221;) and the delivery of the Court Order (as defined in the Transaction Agreement) to the Registrar of Companies in Dublin, Ireland. On October&#160;5, 2023, the Court sanctioned the Scheme. On October&#160;6, 2023, the Court Order was delivered to the Registrar of Companies, at which time the Scheme became effective (the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;).</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">At the Effective Time, Acquirer Sub acquired all of the outstanding ordinary shares of Horizon of nominal value $0.0001 per share (the &#8220;<span style="text-decoration:underline">Ordinary Shares</span>&#8221;) other than Ordinary Shares held by Horizon or its subsidiaries (such acquired Ordinary Shares, collectively, the &#8220;<span style="text-decoration:underline">Horizon Shares</span>&#8221;) and each holder of Horizon Shares outstanding as of 11:59 p.m. New York City time on October&#160;5, 2023, the business day prior to the occurrence of the Effective Time (the &#8220;<span style="text-decoration:underline">Scheme Record Time</span>&#8221;), obtained the right to receive $116.50 in cash in exchange for each Horizon Share (the &#8220;<span style="text-decoration:underline">Consideration</span>&#8221;). In respect of the Horizon Shares issued and outstanding as of the Scheme Record Time, Amgen paid an aggregate of approximately $26.7 billion in cash to former shareholders of Horizon.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the Transaction Agreement, at the Effective Time, each outstanding equity award with respect to Horizon Shares (other than certain restricted stock unit awards denominated in Horizon Shares (&#8220;<span style="text-decoration:underline">Horizon RSUs</span>&#8221;)) was, whether vested or unvested, cancelled and converted into the right to receive the Consideration (less the applicable exercise price in the case of options). Other than any Horizon RSUs granted to <span style="white-space:nowrap">non-employee</span> directors or former service-providers of Horizon as of the completion date for the Acquisition (which Horizon RSUs were canceled and converted into the right to receive the product of the Consideration, <span style="font-style:italic">multiplied</span> by the total number of Horizon Shares subject to such Horizon RSUs immediately prior to the Effective Time), all Horizon RSUs were assumed by Amgen and converted into restricted stock units (each, an &#8220;<span style="text-decoration:underline">Amgen RSU</span>&#8221;) denominated in shares of common stock of Amgen, par value $0.0001 per share (&#8220;<span style="text-decoration:underline">Amgen Common Stock</span>&#8221;), with the number of shares of Amgen Common Stock subject to each such Amgen RSU equal to the product (rounded down to the nearest whole number) of (i)&#160;the number of Horizon Shares subject to such Horizon RSUs immediately prior to the Effective Time <span style="font-style:italic">multiplied</span> by (ii)&#160;(x)&#160;the Consideration divided by (y)&#160;the volume weighted average of the per share closing price of Amgen Common Stock on the Nasdaq Global Select Market (as reported in the Eastern Edition of <span style="font-style:italic">The Wall Street Journal</span> or, if not reported thereby, another authoritative source) for five trading days ending on the second business day prior to the completion of the Acquisition.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">In connection with the completion of the Acquisition, trading of the Horizon Shares on the Nasdaq Global Select Market (the &#8220;<span style="text-decoration:underline">Nasdaq</span>&#8221;) was halted and the Horizon Shares will be delisted from the Nasdaq. Pursuant to the terms of the Transaction Agreement, Amgen and Horizon will take steps to cause the Horizon Shares to be deregistered under the Securities Exchange Act of 1934 (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;) as promptly as practicable following the Effective Time.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing descriptions of the Transaction Agreement and Appendix 3 to the Rule 2.7 Announcement (the &#8220;<span style="text-decoration:underline">Conditions Appendix</span>&#8221;) do not purport to be complete and are subject to, and qualified in their entireties by, the full text of the Transaction Agreement and the Conditions Appendix, which were filed as Exhibit 2.1 and Exhibit 2.2, respectively, to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen with the SEC on December&#160;12, 2022, and are incorporated by reference into this Item 2.01.</p><p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-1-</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;2.03</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Creation of a Direct Financial Obligation or an Obligation Under an <span style="white-space:nowrap">Off-</span> Balance Sheet Arrangement of a Registrant.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">As previously reported, on December&#160;22, 2022, Amgen entered into a Term Loan Credit Agreement (the &#8220;<span style="text-decoration:underline">Term Loan Credit Agreement</span>&#8221;) among Amgen, Citibank, N.A. (&#8220;<span style="text-decoration:underline">Citibank</span>&#8221;), as administrative agent, Bank of America, N.A. (&#8220;<span style="text-decoration:underline">Bank of America</span>&#8221;), as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents. On October&#160;6,&#160;2023, Amgen borrowed $4&#160;billion under the Term Loan Credit Agreement to fund a portion of the Consideration paid to Horizon shareholders and to pay other funding obligations and fees in connection with the Acquisition.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The description of the Term Loan Credit Agreement contained in this Item 2.03 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Term Loan Credit Agreement, which was filed as Exhibit 10.1 to Amgen&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on December&#160;22, 2022 and is incorporated by reference into this Item 2.03.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Regulation FD Disclosure.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;6, 2023, Amgen issued a press release announcing the successful completion of the Acquisition. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 7.01.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:96%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex21.htm">Transaction Agreement, dated as of December&#160;11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc., incorporated by reference to Exhibit&#160;2.1 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen with the SEC on December&#160;12, 2022.</a>*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex22.htm">Appendix 3 to the Rule 2.7 Announcement, dated as of December&#160;12, 2022 (Conditions Appendix), incorporated by reference to Exhibit&#160;2.2 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen with the SEC on December&#160;12, 2022</a>.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d534754dex991.htm">Press Release, dated October&#160;6, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</td></tr></table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Certain schedules have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</p><p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2-</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">&#8195;&#8195;&#8195;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">AMGEN INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;6, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan P. Graham</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jonathan P. Graham</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and General Counsel and Secretary</td></tr></table></div></div></body></html>
